Kabazitaksel Ever Pharma (Cabazitaxel)

• Cabazitaxel is a taxane chemotherapy used in the management of advanced prostate cancer, specifically targeting disease that no longer responds to hormonal therapy.
• Metastatic castration‑resistant prostate cancer: improves overall survival and disease control in patients who have progressed after prior docetaxel therapy.
• Second‑line treatment after docetaxel failure: offers an alternative chemotherapy option to extend survival in advanced prostate cancer.

• Cabazitaxel binds to the β‑tubulin subunit of microtubules, promoting tubulin polymerization and stabilizing the microtubule network. This prevents depolymerization during cell division, leading to mitotic arrest, inhibition of tumor cell proliferation, and induction of apoptosis in rapidly dividing cancer cells. The drug is not a substrate for P‑glycoprotein, allowing activity in taxane‑resistant tumors, and its effect is dose‑dependent. Overall, cabazitaxel disrupts the mitotic spindle, leading to cell death.

Cabazitaxel may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Neutropenia: low white blood cell count increasing infection risk.
• Fatigue: persistent tiredness affecting daily activities.
• Nausea: feeling of sickness often accompanied by vomiting.
• Alopecia: hair loss on scalp and body.

Serious or Rare Side Effects

• Febrile neutropenia: fever with neutropenia requiring urgent medical care.
• Severe allergic reactions: anaphylaxis or hypersensitivity with rash, swelling, and breathing difficulty.
• Pulmonary toxicity: interstitial lung disease or severe breathing problems.

When using Cabazitaxel, clinicians should observe several precautionary measures to minimize risks.

• Monitor blood counts: perform regular complete blood count tests to detect neutropenia or anemia.
• Assess liver function: evaluate hepatic enzymes before and during treatment due to potential hepatotoxicity.
• Evaluate for hypersensitivity: screen patients for prior allergic reactions to taxanes.
• Use cautiously in neuropathy: consider dose adjustments for patients with pre‑existing peripheral neuropathy.
• Avoid in uncontrolled infection: postpone administration if active severe infection is present.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake the solution.

Cabazitaxel can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce cabazitaxel exposure.
• Concurrent use with other myelosuppressive agents: can increase risk of severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase cabazitaxel plasma levels and toxicity.
• Anticoagulants (e.g., warfarin, DOACs): heightened bleeding risk due to possible platelet effects.
• Live vaccines: reduced efficacy and increased infection risk during immunosuppression.